Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från CombiGene via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-01-16 13:29:17
CombiGene has regained the global rights to the epilepsy project CG01 from Spark Therapeutics after the collaboration agreement was terminated last year. BioStock reached out to CombiGene's CEO, Peter Ekolind, for a comment on the plans to continue the project.
Read the interview with Peter Ekolind at biostock.se:
CombiGene: "We continue to believe in the epilepsy project CG01" - BioStock (https://www.biostock.se/en/2024/01/combigene-we-continue-to-believe-in-the-epilepsy-project-cg01/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/